BTC 
ETH 
XRP
SOL 
DOGE - This topic is empty.
-
Posts
-
The FDA has approved Gazyva (obinutuzumab) to reduce the risk of relapse in adult and pediatric patients aged 2 and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome (INS) who are in complete remission, Roche subsidiary Genentech announced on Friday. INS is a rare kidney-related autoimmune disease usually diagnosed in early childhood, and this approval gives families a new steroid-sparing option.
What happened. The approval rests on the Phase III INShore study, in which 95% of patients on Gazyva experienced no relapses after week 8 and were in complete remission at week 52 — one full year — compared with 73% on mycophenolate mofetil (MMF), the conventional comparator. The indication covers both children aged 2 and older and adults who have lived with childhood-onset INS, targeting the frequently relapsing or steroid-dependent forms of the disease while patients are in complete remission.
Why it matters. Steroid-sparing options are the holy grail in pediatric nephrotic syndrome: long courses of corticosteroids control relapses but come with growth, metabolic and behavioral side effects that weigh heavily on children and families. A 95% relapse-free rate at one year versus 73% on MMF is a meaningful efficacy gap, and the approval shows how big pharma is wringing new value out of established biologics — Gazyva, an anti-CD20 monoclonal antibody, has been on the market for years in blood cancers and now extends into rare pediatric autoimmunity. Label expansions like this carry lower R&D risk than de novo programs while opening underserved niches with real pricing power.
What to watch. Uptake in pediatric nephrology practices, where prescribing habits around MMF and other immunosuppressants are entrenched; payer coverage decisions for a rare-disease biologic in children; real-world durability data beyond one year; and whether Roche pursues further indication expansion for obinutuzumab in other autoimmune kidney diseases.
Related reading: FDA Approves AbbVie’s Once-Daily Parkinson’s Pill Juvmo (Tavapadon) and Merck, Daiichi Sankyo Withdraw Lung Cancer Drug BLA After FDA Pushback
Sources: The Pharma Letter
Auto-posted by the Bull Lounge news desk.
Not financial advice.Should insurers cover a premium biologic like Gazyva as first choice for kids with steroid-dependent nephrotic syndrome, or should cheaper options like MMF stay first-line?
Log in to vote
